BiotechTube

Tinlarebant (LBS-008)

Phase 1Completed
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Volunteer

Conditions

Healthy Volunteer, Dry Age-related Macular Degeneration

Trial Timeline

Nov 28, 2022 → Jan 18, 2023

NCT ID
NCT05667688

About Tinlarebant (LBS-008)

Tinlarebant (LBS-008) is a phase 1 stage product being developed by Belite Bio for Healthy Volunteer. The current trial status is completed. This product is registered under clinical trial identifier NCT05667688. Target conditions include Healthy Volunteer, Dry Age-related Macular Degeneration.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05667688Phase 1Completed

Competing Products

20 competing products in Healthy Volunteer

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
33
ValsartanNovartisPhase 1
33
CSL112 + PlaceboCSLPhase 1
32
UT-15CUnited TherapeuticsPhase 1
30
VNA-318 + PlaceboBiotrialPhase 1
25
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
25
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
25
Radiolabeled TRV130TrevenaPhase 1
25
TRV130A + Dextrose in WaterTrevenaPhase 1
25
TRV734TrevenaPhase 1
25
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
33
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
33
KPL-404Kiniksa PharmaceuticalsPhase 1
28
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
33
Propranolol + PseudoephedrineEli LillyPre-clinical
23
LY2157299Eli LillyPhase 1
33
Lasmiditan + PlaceboEli LillyPhase 1
33
LY3015014 + PlaceboEli LillyPhase 1
33
LOXO-783Eli LillyPhase 1
33
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
33

Other Products from Belite Bio

Tinlarebant + PlaceboPhase 3
74
Tinlarebant + PlaceboPhase 3
74
Tinlarebant + PlaceboPhase 2/3
62
tinlarebantPhase 1/2
38
BPN-14967 + PlaceboPhase 1
30